Whistleblower Lawsuit! Government Medicare Data Shows 48,465 DEAD Following COVID Shots – Remdesivir Drug has 25% Death Rate!

Share this:

Back in July of this year we reported that Ohio-based Attorney Thomas Renz was filing a federal lawsuit in Alabama based on a “sworn declaration, under threat of perjury,” from an alleged whistleblower who claims to have inside knowledge of a cover-up of reported deaths filed with the Vaccine Adverse Event Reporting System (VAERS). See:

Attorney Files Lawsuit Against CDC Based on “Sworn Declaration” from Whistleblower Claiming 45,000 Deaths are Reported to VAERS – All Within 3 Days of COVID-19 Shots

Attorney Renz spoke at an event in Colorado this past weekend, and stated that more whistleblowers have now come forward, and that the death rate with those taking the COVID-19 vaccines is much higher than they originally thought.

Presenting data that he claims comes directly from the CMS (Centers for Medicare & Medicaid Services) database, there have been 48,465 deaths among CMS beneficiaries within 14 days of a 1st or 2nd dose of a COVID-19 vaccine.

There are about 59.4 million Americans covered by Medicare, representing 18.1% of the population, so these are staggering numbers!

In his presentation, Renz states that they chose deaths within 14 days of vaccination, because the federal health agencies are no longer counting deaths within 14 days of a COVID-19 as a death among the “vaccinated,” but among “unvaccinated.”

Renz also presented very damning data on the drug Remdesivir, the new COVID-19 drug that was rushed to market while existing, safe and effective older drugs like Ivermectin are prohibited in hospital settings.

According to CMS data, almost 26% of people put on Remdesivir die. But it is a huge money maker for the government and Big Pharma.

By contrast, only 3.5% of people put on…

Read full story [icon name=”arrow-right” prefix=”fas”] Whistleblower Lawsuit! Government Medicare Data Shows 48,465 DEAD Following COVID Shots – Remdesivir Drug has 25% Death Rate!


Share this:
Scroll to Top